A sneak peak into RGC background
Post# of 6702
Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine.
Regencell Chairman and CEO, Yat-Gai Au recently purchased more than $5.9 million in RGC shares.
Majority shareholders of Regencell are insider investors.
Regencell is comfortably poised amidst turbulent market conditions, especially for a biotech stock.
The company has a list of successful clinical trials, with more to come in the year.
https://seekingalpha.com/article/4534812-slow...bioscience